The global methicillin-resistant staphylococcus aureus (MRSA) drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Amongst the variety of microbial flora present in human body, staphylococcus aureus, a gram-positive bacterium, is the most commonly bacteria found on the surface of skin as well as nasal passages of humans. The market growth is majorly attributable to the growing prevalence of staphylococcus aureus all over the globe. According to the US Department of Health (USDoH), 20% of the global population is always colonized with staphylococcus aureus. Being a facultative anaerobe, it can cause respiratory diseases, skin illness, and food poisoning. 

According to the Health Research Funding Organization, nearly 19,000 mortalities are registered globally due to Staph infection every year. According to Center for Disease Control and Prevention (CDC), there were 13 cases in 4 states of US, during 2002-2013. In due course of time, the species of Staphylococcus aureus have developed resistance to many of the antimicrobial drugs such as the MRSA, a class of staphylococcus aureus which is resistant to methicillin. Other than the majorly known Staph infection, it is also the common contributing agent for illnesses such as boils, impetigo, pimples, abscesses, and certain serious diseases such as pneumonia, meningitis, osteomyelitis, sepsis, and others. Thus, to treat such illnesses, the global staphylococcus aureus CA MRSA drug market is likely to grow further during the forecast period. 

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Drug Class

o By Route of Administration

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape:  Pfizer Inc., Merck & Co., Inc., and AbbVie Inc., among others.

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How are players addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drug Market Report by Segment

By Drug Class

• Lipopeptides
• Oxazolidinones
• Cephalosporin
• Tetracycline
• Folate Antagonist
• Others

By Route of Administration

• Oral
• Parenteral

Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drug Market Report by Region

North America       

• US

• Canada

Europe

• Germany

• UK

• France

• Spain

• Italy

• Rest of Europe

Asia-Pacific    

• China

• Japan

• India

• Rest of Asia-Pacific

Rest of the World

• Latin America

• Middle East and Africa